Published in Blood Weekly, March 31st, 2005
In preclinical studies, Cellerant's MP cell product resulted in a survival benefit in immune-compromised mice exposed to lethal fungal infections.
"These experiments lay the foundation for Cellerant's myeloid progenitor product program: a cell product that can be manufactured and given to patients like a drug, without the kind of immunologic matching that currently limits cell therapy," stated Timothy Fong, VP of Research at Cellerant.
"Cellerant is pleased to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.